How bacterial vaginosis is treated
Bacterial vaginosis (BV) is an imbalance of the natural bacteria found in the vagina. While it is not considered a sexually transmitted infection, it can cause symptoms that are uncomfortable and occasionally lead to complications if left untreated. For symptomatic BV, the standard medical approach involves antimicrobial therapy designed to restore the vaginal bacterial balance.
In the UK, symptomatic BV is typically treated with antibiotics prescribed by a GP or a sexual health clinic. The two most common antibiotic classes used for this purpose are metronidazole and clindamycin. These medications can be administered in different ways, including as oral tablets taken by mouth or as vaginal gels and creams applied directly to the affected area.
Because BV has a tendency to recur after apparently successful treatment, managing the condition often involves more than just a single course of medication. While antibiotics are effective at clearing active symptoms, they do not always prevent future episodes. Understanding the available treatment options, from standard multi-day regimens to alternative therapies and preventive strategies, is essential for effective management. Detail how these treatments work, when they should be used, and what precautions are necessary.
Confirming BV before choosing treatment
Before starting any treatment for bacterial vaginosis, it is important to confirm the diagnosis. Many women self-diagnose based on common symptoms such as a thin grey-white discharge or a strong fishy odour. These symptoms are not specific to BV and can overlap with other vaginal infections, including yeast infections (candidiasis) or sexually transmitted infections (STIs) like trichomoniasis.
Healthcare providers in the UK generally recommend that when BV is suspected, a GP or sexual health clinic will assess the vagina and may take a vaginal swab. This testing helps to confirm the presence of BV and rule out other conditions that require different treatments. For example, marked soreness or itching is less typical of BV alone and should raise consideration of another cause, such as a yeast infection or an allergic reaction.
Diagnosis is particularly important in specific situations. Asymptomatic BV does not always require treatment in non-pregnant women, but pregnancy and certain medical procedures (such as before a hysterectomy) change the risk-benefit calculation. In these cases, screening and treatment are often recommended to prevent complications. Relying solely on over-the-counter products without a clear diagnosis can lead to ineffective treatment or mask a more serious underlying condition.
First-line antibiotic options in the UK
The primary treatment for symptomatic BV in the UK involves established antibiotic regimens. Clinical guidelines and product information consistently recommend metronidazole and clindamycin as first-line antimicrobial treatments. There are two main routes of administration: oral tablets and topical vaginal therapies. Patients and clinicians often choose between these based on convenience, tolerance of side effects, and personal preference.
Oral Metronidazole
The most common UK regimen involves taking metronidazole 400 mg tablets by mouth twice daily for 5 to 7 days. This option is widely prescribed and is generally effective at resolving symptoms. Because it is systemic (working throughout the body), it treats the infection internally but may also cause gastrointestinal side effects such as nausea or a metallic taste in the mouth.
Vaginal Metronidazole Gel
An alternative is metronidazole 0.75% vaginal gel. This is applied intravaginally once daily, using one applicatorful (5 g), for 5 days. The topical route delivers the antibiotic directly to the site of infection, which can reduce systemic side effects like nausea. Some women may find the application process inconvenient or messy.
Vaginal Clindamycin Cream
Clindamycin 2% vaginal cream is another first-line option, particularly for those who cannot tolerate metronidazole or in cases where BV recurs after metronidazole treatment. The standard regimen involves applying one applicatorful (5 g) intravaginally at night for 7 days. Clindamycin-based products can weaken latex condoms and diaphragms, requiring specific precautions during use (detailed in Section 6).
Both oral and vaginal options are licensed and recommended in UK guidance. Neither approach is universally superior; the choice often depends on individual tolerance for side effects and the patient's ability to adhere to a daily application routine versus taking oral tablets.
Understanding bacterial vaginosis treatment
Single-dose and alternative prescription treatments
While multi-day regimens are the standard, there are alternative prescription options available in the UK. One such option is a single high dose of metronidazole.
Single-Dose Metronidazole
Current UK product information for metronidazole 400 mg tablets includes a licensed indication for a 2 g single oral dose as an alternative one-day regimen for bacterial vaginosis. This option offers the convenience of a single pill rather than multiple days of medication. Clinical evidence suggests that this approach may be less effective than multi-day treatment. UK NHS guidance notes that there is a higher rate of relapse with a 2 g single dose compared to a 7-day course at four weeks follow-up. While licensed, the single-dose option should not be viewed as automatically equivalent or preferable to the standard multidose regimen, especially for women prone to recurrent symptoms.
Dequalinium Chloride (Fluomizin)
Another UK prescription option is Fluomizin, which contains dequalinium chloride 10 mg in vaginal tablets. The labelled course involves taking one vaginal tablet daily for 6 days. This medication is an antiseptic rather than an antibiotic in the traditional sense. In some NHS formularies, it is restricted to situations where initial first-line treatments are ineffective or not tolerated.
US-Specific Treatments
Patients may encounter information about US-only treatments such as secnidazole (Solosec/Nuvessa) or clindamycin foam/cream formulations marketed under brand names like Clindesse. While these regimens exist in American guidelines, they are not currently part of routine UK prescribing practice. Distinguish between US and UK availability, as competitor articles often conflate the two. In the UK, management remains focused on metronidazole, clindamycin, and dequalinium chloride.
Over-the-counter BV products: what they can and cannot do
There is significant public interest in over-the-counter (OTC) remedies for bacterial vaginosis, including lactic-acid gels, pH-balancing products, and probiotics. These products are not equivalent to prescription antibiotic therapy.
Lactic-Acid and pH-Modifying Gels
Some UK NHS formularies include non-antimicrobial vaginal gels, such as lactic-acid/pH-modifying products, as options in the management of recurrent BV. These products aim to restore the acidic vaginal environment that is disrupted during BV. They do not have the same evidence base for curing active infection as standard antimicrobial treatment.
The distinction in efficacy was clearly demonstrated in the UK VITA randomized trial involving 518 women with symptomatic recurrent BV. The study found that 7 days of oral metronidazole (400 mg twice daily) produced significantly higher symptom resolution at two weeks (70%) compared to 5 ml of intravaginal lactic acid gel once daily for 7 days (47%). While recurrence rates were high in both groups over six months among those who initially improved, metronidazole did lead to more side effects like nausea and diarrhoea.
This trial confirms that while OTC lactic-acid gels may play a role in managing vaginal pH, they are less effective than antibiotics for resolving active symptoms in women with recurrent BV. It is important not to overgeneralize these findings to every commercial product, but the evidence clearly indicates that symptomatic BV requires antibiotic treatment rather than just pH balancing.
Other Home Remedies
Claims regarding yogurt, garlic, douching, or unverified probiotic supplements as cures for BV are not supported by robust clinical evidence. Douching, in particular, can disrupt vaginal flora further and is generally discouraged by healthcare providers. Patients should view OTC products as adjuncts or preventive aids rather than primary treatments for active infection.
Side effects, alcohol, condoms, and treatment precautions
Effective treatment also involves managing side effects and understanding interactions that can affect safety and adherence. Different antibiotic formulations carry different risks and precautions.
Metronidazole and Alcohol
Current UK labelling for oral metronidazole advises avoiding alcohol during the course of treatment and for at least 48 hours afterwards. This caution is due to the potential for a disulfiram-like reaction, which can cause severe nausea, vomiting, flushing, and headache if alcohol is consumed while the drug is still in the system. Patients should read their specific product leaflet carefully. While some international guidelines have debated this interaction, UK product information maintains the restriction.
Metronidazole Drug Interactions
Oral metronidazole can interact with several other medications. Significant interactions include warfarin-type anticoagulants (which may increase bleeding risk), lithium (levels may rise), and disulfiram. Patients taking other regular medications should consult a pharmacist or GP to ensure there are no contraindications before starting treatment.
Clindamycin and Barrier Contraception
Vaginal clindamycin cream has a well-documented effect on latex barrier methods of contraception, including condoms and diaphragms. The cream can weaken latex rubber, increasing the risk of breakage and contraceptive failure. This weakening effect can persist for some time after the treatment course is finished. Patients using clindamycin must refer to their specific product leaflet for the exact duration of avoidance (often up to 5 days after the last dose) and use alternative non-latex barrier methods or abstain from sex during this period.
General Precautions
Oral antibiotics are more likely to cause systemic side effects like gastrointestinal upset, taste disturbances, or headache. Vaginal preparations may cause local irritation, itching, or discharge. Understanding these differences helps patients choose the formulation that best suits their tolerance and lifestyle.
What to do when BV keeps coming back
Recurrence is a common challenge with bacterial vaginosis. NHS guidance indicates that BV can return within a few months of successful treatment. Up to half of women may experience another episode within three months. Recurrent BV requires a different management strategy than initial episodes.
Assessment and Re-treatment
When symptoms return, it is important to have another clinical review rather than simply repeating an old prescription. This ensures that the recurrence is indeed BV and not another condition. For most women, a further course of standard antibiotic treatment (oral or vaginal metronidazole/clindamycin) is prescribed.
Suppressive Treatment for Frequent Recurrence
For women who experience frequent recurrences-defined by the NHS as more than four episodes in a year-clinicians may consider suppressive therapy. This involves a longer duration of treatment to keep the bacterial balance in check. One clinician-directed option available in some NHS local protocols (such as NHS Scotland) is the use of metronidazole vaginal gel twice weekly for 16 weeks. This approach aims to reduce the frequency of relapse rather than just treating acute symptoms.
Adjunctive Non-Antibiotic Therapies
In addition to antibiotic suppression, some local guidelines support the use of non-antimicrobial vaginal gels (like lactic acid) as adjuncts in recurrent BV management. As noted earlier, these are not standalone cures for active symptoms and have a weaker evidence base than antibiotics.
The key principle is that recurrent BV should not be managed by repeated unsupervised short courses of leftover antibiotics. It requires structured, clinician-directed plans tailored to the individual's history of recurrence.
Sex, partners, and the changing evidence on partner treatment
The role of sexual partners in BV management has evolved as research has progressed. Historically, treating male partners was not recommended because BV is not classified as a sexually transmitted infection (STI). Sexual activity can trigger BV, and transmission between partners with vaginas is recognized.
Current NHS Guidance on Partners
The NHS states that while BV is not an STI, sexual activity can pass it on or trigger episodes. If the person with BV has a partner who is a woman or has a vagina, that partner may also need treatment to prevent reinfection or recurrence. This is based on evidence suggesting that female-female transmission plays a role in BV persistence.
New Evidence on Male Partner Treatment (2025)
Recent research has shifted the understanding of male partner involvement. In March 2025, the StepUp open-label randomized trial (Vodstrcil et al.) published findings from monogamous heterosexual couples. The study found that when cis-male partners received treatment (oral metronidazole plus topical clindamycin for 7 days) alongside their female partners, the recurrence rate in women at 12 weeks was significantly lower (35%) compared to women whose male partners did not receive treatment (63%).
Implementation in the UK
Despite these promising results, current UK guidance does not recommend routine self-directed antibiotic treatment for male partners. NHS Dumfries & Galloway local guidance, reflecting broader UK practice, notes the 2025 study but states that concurrent treatment of cis-male partners for recurrent BV should be initiated only by specialists. This cautious approach acknowledges the new evidence while recognizing that universal partner treatment is not yet standard primary care practice in the UK. Patients should discuss this emerging option with their healthcare provider, particularly if they are experiencing frequent recurrences.
BV treatment during pregnancy
Bacterial vaginosis during pregnancy requires careful clinical assessment due to potential associations with pregnancy complications, such as preterm birth or low birth weight. While the link between untreated BV and adverse outcomes is stronger in women with a history of preterm delivery, current NHS guidance advises that pregnant women who notice changed vaginal discharge or suspect BV should speak to their GP or midwife.
Treatment Decisions in Pregnancy
Symptomatic BV in pregnancy may require treatment. The choice of regimen is more restricted than in non-pregnant women. Current UK metronidazole product information states that metronidazole should be used in pregnancy or lactation only when the physician considers it essential. Short high-dose regimens (such as the 2 g single dose) are not recommended in these circumstances.
Preferred Approaches
If treatment is deemed necessary during pregnancy, healthcare providers typically opt for multi-day regimens (e.g., 5-7 days of oral or vaginal metronidazole) rather than single-dose options, adhering to the principle that short high-dose courses are discouraged in pregnancy. Self-treatment with OTC products or leftover antibiotics is not advised during pregnancy. Professional assessment ensures that the benefits of treatment outweigh any potential risks and that other causes of discharge (such as infection) are ruled out.
When to seek medical care
While BV is a common condition, it is not always straightforward to manage at home. Certain symptoms and circumstances warrant prompt clinical assessment rather than reliance on over-the-counter products or repeated self-treatment.
Red Flags for Immediate Care
Seek medical attention if you experience:
- Significant pain: Pelvic or lower abdominal pain that is severe or persistent.
- Systemic illness: Fever, chills, or feeling generally unwell, which may indicate a more serious infection like pelvic inflammatory disease (PID).
- Bleeding: Unusual vaginal bleeding, especially if not related to menstruation.
- Atypical symptoms: Symptoms that do not fit the classic BV profile (e.g., intense itching, redness, or thick white discharge), which may suggest yeast infection or other STIs.
When to Reassess
You should also see a clinician if:
- Symptoms persist after completing a prescribed course of treatment.
- BV recurs frequently (more than four times a year), requiring a specialist management plan.
- You are pregnant and notice any changes in vaginal discharge.
Self-treating with OTC gels for persistent or atypical symptoms can delay the diagnosis of more serious conditions. Accurate diagnosis through swabbing is the safest way to ensure appropriate treatment and protect long-term reproductive health.
Symptomatic bacterial vaginosis (BV) in the UK is usually treated with antibiotics, most often metronidazole or clindamycin, given either orally or vaginally. Multi-day regimens are standard. A single 2 g dose of metronidazole is licensed but may be less effective and has higher relapse rates than multi-day treatment. Dequalinium chloride is another UK prescription option in some settings, while treatments available only in the US are not part of routine UK practice. Because BV symptoms overlap with yeast infections and STIs, diagnosis should be confirmed before treatment, especially if symptoms are atypical or the person is pregnant or preparing for certain procedures; asymptomatic BV does not always require treatment in non-pregnant women.
Over-the-counter lactic-acid/pH gels and probiotics are not equivalent to antibiotics for active infection. In a UK trial of women with recurrent BV, oral metronidazole gave higher symptom resolution than an intravaginal lactic-acid gel, although recurrence was high in both groups. Other home remedies such as yogurt, garlic, douching, or unverified probiotics are not supported; douching is discouraged. Recurrence is common, and frequent recurrence requires clinical review and a structured clinician-directed plan, which may include longer suppressive treatment and, in some local guidelines, non-antimicrobial gels as adjuncts, rather than repeated unsupervised leftover antibiotics.
On partners, NHS guidance says BV is not an STI, but sexual activity can trigger it and a partner who is a woman or has a vagina may need treatment. A 2025 trial found lower recurrence when cis-male partners were treated alongside their female partners, but UK guidance does not recommend routine self-directed antibiotic treatment for male partners; specialist initiation is advised for recurrent BV.
Safety and interaction precautions matter. Oral metronidazole requires avoiding alcohol during treatment and for at least 48 hours afterwards because of a possible disulfiram-like reaction, and it can interact with warfarin-type anticoagulants, lithium, and disulfiram. Vaginal clindamycin cream can weaken latex condoms and diaphragms, so alternative non-latex barrier methods or abstaining from sex is needed according to the product leaflet. In pregnancy or lactation, metronidazole should be used only when a physician considers it essential; short high-dose regimens are not recommended, and multi-day treatment is typically preferred. Seek prompt care for severe pelvic or abdominal pain, fever/chills or feeling generally unwell, unusual bleeding, or atypical symptoms, and see a clinician if symptoms persist, BV recurs frequently, or pregnancy discharge changes.
Before treating BV, the diagnosis should be confirmed. Symptoms such as thin grey-white discharge or a fishy odour overlap with yeast infections and STIs, so a GP or sexual health clinic may assess the vagina and take a swab; marked soreness or itching is less typical of BV alone. Asymptomatic BV does not always require treatment in non-pregnant women, but pregnancy and certain procedures such as hysterectomy change the risk-benefit balance, and screening and treatment are often recommended to prevent complications. Relying on over-the-counter products without a clear diagnosis can lead to ineffective treatment or mask a more serious condition.
During pregnancy, BV requires careful clinical assessment because it has been associated with complications such as preterm birth or low birth weight, with a stronger link in women who have a history of preterm delivery. Pregnant women who notice changed vaginal discharge or suspect BV should speak to their GP or midwife. Symptomatic BV in pregnancy may require treatment, but the regimen is more restricted: UK metronidazole product information states it should be used in pregnancy or lactation only when the physician considers it essential, and short high-dose regimens are not recommended. Multi-day regimens, such as 5 to 7 days of oral or vaginal metronidazole, are typically preferred, and self-treatment with over-the-counter products or leftover antibiotics is not advised.
Over-the-counter BV products are not equivalent to prescription antibiotic therapy for active infection. Some NHS formularies include lactic-acid/pH-modifying vaginal gels as options in the management of recurrent BV, but they do not have the same evidence base for curing active infection. In a UK trial of women with symptomatic recurrent BV, 7 days of oral metronidazole produced higher symptom resolution at two weeks than intravaginal lactic-acid gel; recurrence rates were high in both groups over six months among those who initially improved, and metronidazole caused more side effects such as nausea and diarrhoea. Yogurt, garlic, douching, and unverified probiotic supplements are not supported by robust evidence, and douching is generally discouraged. Over-the-counter products should be viewed as adjuncts or preventive aids, not primary treatments for active infection.
Recurrence is common: NHS guidance indicates BV can return within a few months of successful treatment, and up to half of women may experience another episode within three months. When symptoms return, arrange another clinical review rather than simply repeating an old prescription, because the recurrence may not be BV. For most women, a further course of standard antibiotic treatment is prescribed. For frequent recurrence, defined by the NHS as more than four episodes a year, clinicians may consider suppressive therapy, such as metronidazole vaginal gel twice weekly for 16 weeks in some local protocols. Some local guidelines also support non-antimicrobial vaginal gels as adjuncts, but these are not standalone cures and have a weaker evidence base than antibiotics. Recurrent BV should not be managed by repeated unsupervised short courses of leftover antibiotics; it requires a structured, clinician-directed plan.
On partners, NHS guidance states that BV is not an STI, but sexual activity can pass it on or trigger episodes, and a partner who is a woman or has a vagina may need treatment to prevent reinfection or recurrence. A 2025 open-label randomised trial in monogamous heterosexual couples found lower recurrence at 12 weeks when cis-male partners received oral metronidazole plus topical clindamycin for 7 days alongside their female partners. Current UK guidance does not recommend routine self-directed antibiotic treatment for male partners; concurrent treatment of cis-male partners for recurrent BV should be initiated only by specialists. Patients should discuss this emerging option with their healthcare provider, particularly if they are experiencing frequent recurrences.
Published by: NHS
Published by: British Association for Sexual Health and HIV
Published by: Centers for Disease Control and Prevention
Questions and feedback
Please leave out passwords, medical record numbers, insurance details, financial information, exact addresses, and any other confidential or directly identifying details from your message.